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Purpose: The vascular smooth muscle determines the dynamic aliber of the blood vessel 
and hence is the final effector cell in modulating vasomotor tone. Although considerable 
information isavailable regarding the physiologic agonists that induce contraction, less is 
known about the cellular signaling events that lead to long-lasting contractions r 
vasospasm. We examined the hypothesis that activation of mitogen-activated protein 
(MAP) kinase may be associated with sustained smooth muscle contractions. 
Methods: Physiologic ontractile responses were determined in intact bovine carotid artery 
smooth muscles in a muscle bath. Corresponding signaling events were determined with 
immtmoblots using antiphosphotyrosine antibodies or immunoprecipitation f whole- 
cell phosphorylated strips of muscle. 
Results: The tyrosine kinase inhibitor, genestein, significantly inhibited the magnitude of 
contractions induced by phorbol ester, endothelin, angiotensin, and serotonin. In addi- 
tion, genestein inhibited the sustained phase of contractions induced by serotonin. 
Serotonin-induced vascular smooth muscle contractions were temporally associated with 
an increase in the phosphorylation f MAP kinase. 
Conclusions: These data suggest hat the activation of MAP kinase is associated with 
sustained vascular smooth muscle contractions. Pharmacologic manipulation of MAP 
kinase activation may lead to new approaches to treat pathologic circumstances of 
increased vasomotor tone such as vasospasm. (J Vasc Surg 1997;26:327-32.) 
The vascular smooth muscle controls the dy- 
namic caliber of blood vessels and is the primary 
effector cell in the regulation of vasomotor tone. 
Increases in vasomotor tone lead to hypertension and 
vasospasm, whereas decreases in vasomotor tone lead 
to hypotension and shock. Many autocrine, para- 
crine, neurocrine, mechanical, and ionic factors 
modulate smooth muscle tone. Although the list of  
vasoactive substances is extensive, less is known 
about the signaling events hat modulate vascular 
smooth muscle tone on a cellular level. 
One cellular signaling mechanism that has been 
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implicated in the initiation of vascular smooth mus- 
cle contraction involves increases in intracellular 
Ca 2+, which leads to activation of myosin light chain 
ldnase (MLCK).I MLCK phosphorylates the regula- 
tory myosin light chains (MLC20), which activates 
actinomyosin adenosine triphosphatase. 1,2 However, 
recent studies have shown that vascular smooth mus- 
cles can maintain contractions in the absence of in- 
creases in intracellular Ca 2+, increases in MLC20 
phosphorylation, and energy consumption. 3-s Thus 
the mechanisms by which long-lasting contractions 
(the so-called "latch state") are maintained have not 
been clearly identified. This has led many investiga- 
tors to propose that alternative signaling pathways 
may also regulate vascular smooth muscle contrac- 
tion. 
One hypothesis i that a ldnase cascade involving 
activation of protein ldnase C (PKC), mitogen-acti- 
vated protein (MAP) ldnase, and the subsequent 
phosphorylation of regulatory thin filaments results 
in the maintenance of force in vascular smooth mus- 
cle. s,6 To test this hypothesis, we examined contrac- 
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tile physiologic and cellular signaling events in intact, 
functionally viable vascular smooth muscles from bo- 
vine carotid arteries. 
MATERIALS AND METHODS 
Materials. Antiphosphotyrosine antibodies were 
obtained from Transductlon Labs (Lexington, Ky.), 
and anticaldesmon antibodies were a generous gift 
from Dr. Len Adam (Boston). Immobilon-P was 
purchased from Millipore (Bedford, Mass.) and 
[32P]-orthophosphate from Amersham (Arlington 
Heights, Ill.). Physiologic agonists, protein A sepha- 
rose beads, and other chemicals were of analytical 
grade and were purchased from Sigma Chemical (St. 
Louis). 
Contractile physiologic mechanism. Fresh bo- 
vine calf carotid arteries were obtained from a local 
abattoir. The vessels were dissected free of adventitial 
tissues, opened longitudinally, and the endothelium 
denuded. Morphologic confirmation of endothelial 
denudation with this technique has been previously 
determined. 7 Strips of muscle (1 mm in width) were 
placed in a muscle bath, and contractile responses 
were determined in a muscle bath as previously de- 
scribed, s Length-tension relationships were maxi- 
mized at the start of each experiment, and all re- 
sponses are normalized to the maximal high KC1 
(110 mmol/L) contraction. 
Immunoblotting. Intact strips of bovine ca- 
rotid arteries denuded of endothelium were stimu- 
lated with serotonin for the appropriate time points. 
The muscles were flash-frozen in a slurry of dry 
ice/acetone and were subsequently crushed using a 
mortar and pestle under liquid N 2. The pulverized 
sample was placed in cold homogenization buffer (60 
mmol/L Tris, 0.25 mol/L sucrose, 10 mmol/L 
ethyleneglycol- bis- ([3-aminoethylether)-N,N,N',N'- 
tetraacetic acid (EGTA), 2 mmol/L ethylenediamine 
tetraacetic acid, 10 mmol/L 2-mercaptoethanol, pH 
7.4), and the 10,000 X g supernatant was protein 
weighted using the Coomassie Plus Protein Assay 
(Pierce, Rockford, Ill.). The sample was diluted 1:1 
with 2X sample buffer (0.5 mol/L Tris, 200 
mmol/L EGTA, 4% sodium dodecylsulfate, 20% 
glycerol, 1% bromphenol blue, pH 6.8), and the 
proteins were separated on 10% sodium dodecylsul- 
fate-polyacrylamide gel electrophoresis (SDS- 
PAGE) gels. The proteins were transferred to Immo- 
bilon-P membranes, blocked with 100 mmol/L Tris 
(pH 7.4), 150 mmol/L NaCI, 3% bovine serum 
albumin, washed with 100 mmol/L Tris (pH 7.4), 
150 mmol/L NaC1, 0.5% Tween 20, and probed 
with mouse antlphosphotyrosine antibody (1:5000 
in block buffer for 1 hour). Immunoreactive proteins 
were detected using peroxidase-conjugated goat an- 
timouse (1:2000 in block buffer) and Western blot 
chemiluminescence r agent (DuPont-NEN, Bos- 
ton). 
Whole cell phosphorylation and caldesmon 
immunoprecipitation. Strips of bovine carotid ar- 
teries were equilibrated in bicarbonate buffer (120 
mmol/L NaC1, 4.7 mmol/L KCI, 1.0 mmol/L 
MgSO4, 1.0 mmol/L NaHPO4, 10 mmol/L glu- 
cose, 1.5 mmol/L CaC12, and 25 mmol/L 
Na2HCO3) at 37 ° C and gassed with 95% 02, 5% 
CO 2 for 1 hour. The strips were then placed in 
a low-phosphate N-2-hydroxyethylpiperazine-N-2- 
ethanesulfonic acid (HEPES) buffer (140 mmol/L 
NaC1, 4.7 mmol/L KC1, 1.0 mmol/L MgSO4, 10 
mmol/L glucose, 1 mmol/L CaC12, and 10 
mmol/L HEPES, pH 7.4) at 37 ° C, with intermit- 
tent oxygenation every 20 minutes for 90 minutes. 
Muscle strips were then incubated in low-phosphate 
buffer containing 250 IxCi/ml [a2p]-orthophosphate 
for an additional 90 minutes to label cellular adeno- 
ine triphosphate pools. Some strips were stimulated 
with serotonin, and then immersed in acetone/dry 
ice. The tissue was then crushed using a mortar and 
pestle under liquid N 2. 
Immunoprecipitation of caldesmon was per- 
formed as described by Adam et al. 8 using polyclonal 
antiserum against chicken gizzard caldesmon. After 
protein weighting, the immunoprecipitates were sep- 
arated by SDS-PAGE using 8% gels, followed by 
autoradiography. Changes in phosphorylation were 
quantified by digitalizing the images with a CCD 
camera interfaced with an IS 1000 Digital Imaging 
System (Alpha Innotech Corp., San Lean&o, Calif.). 
Statistical analysis. Results are reported as 
mean _+ standard error of the mean. Statistical analy- 
sis was by analysis of variance using Dunnett's 
method for pairwise multiple comparisons and Sig- 
mastat software (Jandel Scientific, San Rafael, Calif.) 
with a p value less than 0.05 considered significant. 
All experiments were performed at least in triplicate. 
RESULTS 
Strips of bovine carotid artery smooth muscle 
were preincubated with the tyrosine ldnase inhibitor, 
genestein (50 ~mol/L for 15 minutes). Preincuba- 
tion with genestein significantly inhibited the maxi- 
mal contractions induced by phorbol dibutyrate 
(10 7 tool/L, 45 minutes), serotonin (5-hydroxy- 
tryptamine, 1 b~mol/L, 5 minutes), angiotensin II
(10 -6 tool/L, 5 minutes), and endothelin-1 ( 0 -7 
mol/L, 15 minutes), but not by high extracellular 
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Fig. l. Strips of bovine carotid artery smooth muscle 
were equilibrated in a muscle bath. Strips were then prein- 
cubated in the presence (+) or absence (-)  of the tyrosine 
ldnase inhibitor genestein (50 ~mol/L) for 15 minutes 
followed by treatment with the specific vasoactive agonists, 
high extracellular KC1 (110 mmol/L), phorbol dibutyrate 
(10 -7 mol/L), serotonin (10 -6 mol/L), angiotensin II
(10 6 mol/L), or endothelin-1 ( 0 7 mol/L). Genestein 
significantly inhibited contractions induced by phorbol 
dibutyrate, serotonin, a giotensin II, and endothelin-1 
(*p < 0.05, analysis of variance, three different arteries for
each agonist) but did not inhibit contractions induced by 
high extracellular KC1. 
KCI (110 mmol/L ,  5 minutes; Fig. 1). The doses of 
agonists were chosen that produced a submaximal 
contraction, s,9 The inhibitory effect of genestein ap- 
peared more pronounced with serotonin-induced 
contractions, but this was not statistically different 
from endothelin-1 or angiotensin II-induced con- 
tractions. 
In addition to inhibiting the maximal tension 
induced by serotonin, preincubation with genestein 
also inhibited the sustained phase of contraction 
(Fig. 2). Contractions induced by serotonin (1 
txmol/L) maintained a maximal evel of tension in 
the absence ofgenestein, but muscles pretreated with 
genestein relaxed back to baseline ven though sero- 
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Fig. 2. Strips of bovine carotid artery smooth muscle 
were equilibrated in a muscle bath and preincubated with 
buffer (closed circles) or genestein 50 ixmol/L (closed 
squares) for 15 minutes. Strips were th n treated with 
serotonin (1 txmol/L), and the contractile responses were 
recorded. Pretreatment with genestein significantly inhib- 
ited the maximal contractile response induced by serotonin 
(*p < 0.05, three separate experiments) and abolished the 
sustained phase of contraction. 
tonin remained in the bath solution (Fig. 2). There 
was no difference in the rate of the initiation of 
contraction between the muscles pretreated with 
genestein compared with control muscles. 
To determine whether serotonin-induced con- 
tractions were t mporally associated with the activa- 
tion of MAP kinase, immunoblots were performed 
with antiphosphotyrosine a tibodies. Tyrosine phos- 
phorylation of MAP kinase is associated with activa- 
tion of the ldnase) ° Immunoblots with antibodies 
specific for the tyrosine phosphorylated proteins 
demonstrated an increase in tyrosine phosphoryla- 
tion of MAP kinase with serotonin stimulation of 
bovine carotid artery smooth muscle (Fig. 3, A). The 
phosphorylation f MAP ldnase peaked at a similar 
time point as the maximal contractile response (3 
minutes) and declined but remained above baseline 
after 30 minutes of serotonin (1 Ixmol/L) stimula- 
tion (Fig. 3, C). Finally, preincubation with genest- 
ein prevented the increase in tyrosine phosphoryla- 
tion of MAP kinase with serotonin stimulation (Fig. 
3, B and C). 
The phosphorylation f the thin filament regula- 
tory protein, caldesmon, by MAP kinase, has been 
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Fig. 3. Strips of bovine carotid artery smooth muscle 
were treated with serotonin (1 ixmol/L; A). Some strips 
were pretreated with genestein (50 ~mol/L; B). Strips 
were homogenized at the various time points indicated, 
and immunoblots were performed with antiphosphoty- 
rosine antibodies. Treatment with serotonin led to an in- 
creasc in tyrosine phosphorylation f the 42 kDa isoform 
of MAP ldnase (arrows). Densitometric analysis demon- 
strated a significant increase in tyrosine phosphorylation, 
which peaked at 3 minutes and remained elevated over 
baseline for 30 minutes (C; closed circles; *p < 0.05 analysis 
of variance, three separate xperiments). Preincubation 
with genestein hibited the increase in tyrosine phosphor- 
ylation of MAP kinase (C; open circles). 
implicated in the maintenance of force. 8 To deter- 
mine whether caldesmon was phosphorylated during 
scrotonin-induced contractions, whole-cell phos- 
phorylation and immunoprecipitation with anti- 
caldesmon antibodies was performed. Caldesmon 
phosphorylation significantly increased after 15 min- 
utes ofserotonin stimulation (Fig. 4). 
DISCUSSION 
Although Ca2+-dependent activation of MLCK 
has been implicated in the initiation of vascular 
smooth muscle contraction, less is lmown about the 
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Fig. 4. Strips of bovine carotid artery smooth muscle 
were phosphorylated and remained in buffer (control, C) 
or were treated with serotonin (S, 1 ~mol/L, 15 minutes). 
Strips were homogenized, and immnnoprecipitation with 
anticaldesmon a tibodies was performed. Autoradiographs 
demonstrate an increase in caldesmon phosphorylation 
with serotonin stimulation (A). Densitometric analysis 
demonstrated that this increase in caldesmon phosphoryla- 
tion was significant (B, *p < 0.05, analysis o f variance, five 
separate experiments). 
events that modulate the sustained phase of contrac- 
tion. Pathologic sustained contraction leads to vaso- 
spasm. Vasospasm has been implicated in a variety of 
disease processes, including myocardial infarction, 
subarachnoid hemorrhage, mesenteric schemia, and 
bypass graft failure. 11-14 Some types of vasospasm, 
such as umbilical artery spasm, vein graft spasm, and 
the spasm that occurs in association with subarach- 
noid hemorrhage, are refractory to pharmacologic 
vasodilators? 5q7 Thus an understanding of the 
mechanisms that lead to the maintenance of  force 
in vascular smooth muscle may lead to new phar- 
macologic approaches to treat these forms ofvaso- 
spasm. 
Recent data suggest that a kinase cascade initiated 
by activation of PKC modulates the sustained vascu- 
lar smooth muscle contractions and may be operative 
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in vasospastic states, s,6,8,12 PKC phosphorylates 
MLC20 at different sites than MLCK, and the phos- 
phorylation of MLC20 by PKC does not activate 
contraction of permeabilized muscles. 18,19 Thus it 
has been proposed that PKC activation lcads to sus- 
tained contraction via the initiation of a kinase cas- 
cade that leads to the phosphorylation f smooth 
muscle contractile regulatory elements such as 
caldesm0n. 
To determine whether activation of the MAP 
ldnase pathway occurs during vascular smooth mus- 
cle contraction, the effect of the tyrosine kinase 
inhibitor, genestein, on vascular smooth muscle con- 
traction was examined. Genestein i hibited contrac- 
tions induced by the PKC activator, phorbol dibu- 
tyrate, and by the physiologic ontractile agonists, 
serotonin, angiotensin II, and endothelin-1 in intact 
bovine carotid arteries (Fig. 1). Inhibition oftyrosine 
phosphorylation with genestein also abolished the 
sustained phase of a serotonin-induced contraction 
in vascular smooth muscle (Fig. 2). However, 
genestein did not inhibit contractions induced by 
high extracellular KC1. KCl induces contractions by 
depolarizing the membrane, allowing an influx of 
Ca2+. 2° Physiologic agonists induce contractions by 
receptor-coupled activation of phospholipases, 
which leads to the production of IP 3 (which releases 
Ca 2+ from the sarcoplasmic reticulum) and diacyl- 
glycerol (which activates PKC). Phorbol dibutyrate 
mimics the effects of diacylglycerol and directly acti- 
vates PKG. Thus these data implicate tyrosine phos- 
phorylation in the sustained phase of agonist-in- 
duced vascular smooth muscle contraction. 
The 42 and 44 kDa MAP kinase isoforms have 
been identified in rat aorta and porcine carotid arter- 
ies. 8,21,22 These two MAP ldnase isoforms are also 
present in bovine carotid artery smooth muscle (Fig. 
3). An increase in the tyrosine phosphorylation f 
predominantly he 42 kDa MAP ldnase isoform was 
temporally associated with serotonin-induced vas- 
cular smooth muscle contraction (Fig. 3). The 
increase in tyrosine phosphorylation f MAP ki- 
nase was inhibited by preincubation of the muscle 
strips with genestein (Fig. 3). This suggests that 
the tyrosine phosphorylation of MAP kinase is 
temporally associated with agonist-induced con- 
tractions. 
Another tyrosine ldnase inhibitor, geldanomycin, 
has been recently shown to inhibit phenylephrine- 
induced contraction of canine carotid artery smooth 
muscle. 23 MAP kinase activation has been demon- 
strated in porcine carotid artery smooth muscles in 
response to high KC1, phorbol dibutyrate, and hista- 
mine stimulation. 22,24 This investigation did not 
demonstrate inhibition of KCl-induced contractions 
with genestein. The differences between the two 
studies may be a result of different tissues examined 
or to differences in methodologic approaches.22 Kha- 
lil and coworkers 2 have recently shown that phenyl- 
ephrine stimulation leads to redistribution of MAP 
kinase from the plasma membrane to the cytoskele- 
ton in ferret aortic cells. Thus the activation of MAP 
kinase may lead to a redistribution of the ldnase to 
the cellular structure containing the contractile reg- 
ulatory machinery. 
MAP kinase has been suggested to regulate 
smooth muscle contractile states by directly phos- 
phorylating caldesmon. 24Caldesmon is a thin fila- 
ment actin binding protein that inhibits the actin- 
activated myosin adenosine triphosphatase activity. 
This inhibition is reversed by the phosphorylation of 
caldesmon. The phosphorylation of caldesmon i - 
creases in vascular smooth muscles timulated with 
high KC1, histamine, and phorbol dibutyrate, s The 
phosphorylation of caldesmon also increases with 
serotonin-induced contractions ofbovine carotid ar- 
tery smooth muscles (Fig. 4). The phosphorylation 
of caldesmon during agonist-induced contractions 
may lead to the dissociation of caldesmon from the 
contractile machinery, thus allowing actin and myo- 
sin to form stable interactions. In addition, Yamada 
and coworkers 26 have shown that a small heat shock 
protein, HSP27, is colocalized with the redistribu- 
tion of MAP kinase in smooth muscle cells. HSP27 is 
abundant in muscle tissues and has been shown to 
modulate actin filament dynamics in vitro. 27 Thus 
activation of MAP ldnase may lead to sustained con- 
traction through an interaction with the actin regu- 
latory proteins, caldesmon, HSP27, or a combina- 
tion of these. 
This study demonstrated that the tyrosine kinase 
inhibitor, genestein, decreases the magnitude of con- 
tractions induced by angiotensin II, endothelin-1, 
and serotonin; that genestein hibited the sustained 
phase of serotonin-induced vascular smooth muscle 
contractions; and that there was a temporal associ- 
ation between vascular smooth muscle contraction 
and the tyrosine phosphorylation f MAP kinase. 
Taken together, these data and the data of others 
support a role for the sequential activation of the 
protein kinases, PKC, and MAP kinase, with the 
subsequent phosphorylation f specific actin regu- 
latory proteins in the regulation of force mainte- 
nance in agonist-induced vascular smooth muscle 
contractions. Manipulation of this pathway with 
pharmacologic tyrosine kinase inhibitors may pro- 
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vide novel approaches to the treatment of  vaso- 
spasm. 
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